Related Experiment Video

Updated: Jul 29, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction

M Terashima1, H Akita, K Kanazawa

  • 1First Department of Internal Medicine, Kobe University School of Medicine, Kobe, and Himeji Cardiovascular Center, Hyogo, Japan.

Circulation
|June 3, 1999
PubMed
Abstract

Insights

A common genetic variant, the 5A/6A polymorphism in the stromelysin gene promoter, is a significant risk factor for acute myocardial infarction (AMI). This finding highlights a novel pathway contributing to heart attacks.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Pathogenesis of Atherosclerosis

Background:

  • Plaque rupture is a critical event leading to acute myocardial infarction (AMI).
  • Matrix metalloproteinases (MMPs), including stromelysin, are implicated in weakening atherosclerotic plaque caps.
  • A common 5A/6A polymorphism in the stromelysin gene promoter may influence gene transcription.

Purpose of the Study:

  • To investigate the association between the stromelysin gene 5A/6A polymorphism and the risk of AMI.
  • To determine if this genetic variant is an independent risk factor for AMI.

Main Methods:

  • A case-control study was conducted with 330 AMI patients and 330 control subjects.
  • Genotyping for the 5A/6A polymorphism in the stromelysin gene promoter was performed.
  • Statistical analysis, including logistic regression, was used to assess the association.

Main Results:

  • The 5A/6A+5A/5A genotype was significantly more prevalent in AMI patients (48.8%) compared to controls (32.7%).
  • The odds ratio for AMI associated with the 5A/6A+5A/5A genotype was 2.25.
  • The association remained statistically significant and independent of other cardiovascular risk factors.

Conclusions:

  • The 5A/6A polymorphism in the stromelysin gene promoter represents a novel pathogenetic risk factor for AMI.
  • This genetic variant may play a role in the development and progression of acute myocardial infarction.

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

Related Concept Videos

Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...